Back to Search
Start Over
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.
- Source :
-
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2013 Nov; Vol. 9 (11), pp. 2427-33. Date of Electronic Publication: 2013 Jul 09. - Publication Year :
- 2013
-
Abstract
- Background: The long-term prognosis of patients with stage IV AJCC melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine.<br />Results: In this study we report on a better than expected long-term survival (3-y DSS 29·6%, 5-y, and 7-y DSS both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. Although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected.<br />Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004.<br />Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.
- Subjects :
- Adult
Aged
Cancer Vaccines immunology
Female
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic
Survival Analysis
Treatment Outcome
Vaccines, Inactivated immunology
Vaccines, Inactivated therapeutic use
Cancer Vaccines therapeutic use
Melanoma therapy
Mycobacterium immunology
Neoplasm Metastasis therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2164-554X
- Volume :
- 9
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Human vaccines & immunotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 23863507
- Full Text :
- https://doi.org/10.4161/hv.25618